dr. reddy's labs glp-1 receptor agonist Agonists: The New Wave in Diabetes Management Dr. Reddys Laboratories DMF, CEP,

Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects

To add to that, the STEP HFpEF trial conducted by Novo Nordisk showed that semaglutide could cut down the risk of heart failure

The FDA sets the floor

Irrespective of the challenges such as adverse effects associated with weight management medicines such as nausea and diarrhea and lack of combination therapy, the global obesity drugs market has high potential to grow at a significant rate and is expected to gain further momentum in the coming years due to a strong emphasis on new product development, greater acceptance in developing countries, positive impact of social media campaigns, and decreasing pricing trend due to competition, among others

References 1.Drucker D.J